The renin-angiotensin system is involved in the production of plasminogen activator inhibitor type 1 by cultured endothelial cells in response to Chylomicron remnants

Hypertension Research

Volumn 26, Issue 4, 2003, Pages 315-323

  Morimoto, Shinji ^a   Fujioka, Yoshio ^a   Hosoai, Hiroshi ^b   Okumura, Takahiro ^a   Masai, Miho ^a   Sakoda, Tsuyoshi ^a   Tsujino, Takeshi ^a   Ohyanagi, Mitsumasa ^a   Iwasaki, Tadaaki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Central Hospital   (Japan)

Author keywords

Chylomicron remnants; Endothelial cells; Plasminogen activator inhibitor type 1; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CELL EXTRACT; CHYLOMICRON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; OLMESARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TEMOCAPRILAT; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER RESECTION; MALE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UMBILICAL VEIN;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; CHYLOMICRONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIAL CELLS; L-LACTATE DEHYDROGENASE; LIPOPROTEINS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM;

EID: 0038663216     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.315     Document Type: Article

References (49)

1. Vaughan DE: Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. J Invest Med 1998; 46: 370-376.
2. Juhan-Vague I, Alessi M-C, Morange PE: PAI-1, obesity, and insulin resistance, in Reaven GM, Laws A (eds): Contemporary Endocrinology. Totowa, Humana Press, 1999, pp 317-332.
3. Hamsten A, de Faire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
4. Loskutoff DJ, Samad F: The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
5. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
6. Takeda K, Ichiki T, Tokunou T, et al: Critical role of Rhokinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21: 868-873.
7. Nagata K, Ishibashi T, Sakamoto T, et al: Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J Hypertens 2001; 19: 775-783.
8. Hamdan AD, Quist WC, Gagne JB, Feener EP: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-1078.
9. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
10. Nakamura S, Nakamura I, Ma LJ, Vaughan DE, Fogo AB: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 251-259.
11. Poli KA, Tofler GH, Larson MG, et al: Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-269.
12. Asplund-Carlson A, Hamsten A, Wiman B, Carlson A: Relationship between plasminogen activator inhibitor activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridemic men. Diabetologia 1993; 36: 817-825.
13. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J: Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073.
14. Eriksson P, Nilsson L, Karpe F, Hamsten A: Very-low-density lipoprotein response element in the promotor region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-26.
15. Gräfe M, Auch-Schwelk W, Hertel H, et al: Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL. Atherosclerosis 1998; 137: 87-95.
16. Davignon J, Cohn JS: Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996; 124 (Suppl): S57-S64.
17. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-485.
18. Karpe F, Hamsten A: Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1995; 6: 123-129.
19. Fujioka Y, Cooper AD, Fong LG: Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J Lipid Res 1998; 39: 2339-2349.
20. Kugiyama K, Doi H, Takazoe K, et al: Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-2860.
21. Patsch JR, Miesenböck G, Hopferwieser T, et al: Relation of triglyceride metabolism and coronary disease: studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-1345.
22. Haendeler J, Mebmer UK, Brune B, Neugebauer E, Dimmeler S: Endotoxic shock leads to apoptosis in vivo and reduced Bcl-2. Shock 1996; 6: 405-409.
23. Ishii M, Shimizu S, Yamamoto T, Momose K, Kuroiwa Y: Acceleration of oxidative stress-induced endothelial cell death by nitric oxide synthase dysfunction accompanied with decrease in tetrahydrobiopterin content. Life Sci 1997; 61: 739-747.
24. Bligh EG, Dyer WJ: A rapid methods of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
25. Kolarovic L, Fournier NC: A comparison of extraction methods for the isolation of phospholipids from biological sources. Anal Biochem 1986; 156: 244-250.
26. Griglio S, Sultan F, Lagrange D: Role of hepatic lipase in the catabolism of chylomicron remnants in the rat. Diabetes Metab 1992; 18: 150-155.
27. Hayashi T, Tsujino T, Iwata S, et al: Decreased ornithine decarboxylase activity in the kidneys of Dahl salt-sensitive rats. Hypertens Res 2002; 25: 787-795.
28. Iwata S, Tsujino T, Ikeda Y, et al: Decreased expression of arginase II in the kidneys of Dahl salt-sensitive rats. Hypertens Res 2002; 25: 411-418.
29. Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1489.
30. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
31. Banfi C, Mussoni L, Rise P, et al: Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res 1999; 85: 208-217.
32. Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-1855.
33. Chen YB, Billadello JJ, Schneider DJ: Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol 2000; 20: 2696-2701.
34. Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P: Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1679-1685.
35. Allison BA, Nilsson L, Karpe F, Hamsten A, Eriksson P: Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1354-1360.
36. Dichtl W, Stiko A, Eriksson P, et al: Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 3025-3032.
37. Ghanim H, Garg R, Aljada A, et al: Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-1312.
38. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the PAI-1 gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
39. Barnes PJ, Karin M: Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
40. Kugiyama K, Motoyama T, Doi H, et al: Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. JAm Coll Cardiol 1999; 33: 1512-1518.
41. Napolitano M, Rivabene R, Avella M, et al: Oxidation affects the regulation of hepatic lipid synthesis by chylomicron remnants. Free Radic Biol Med 2001; 30: 506-515.
42. Okada H, Woodcock-Mitchell J, Mitchell J, et al: Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. Circulation 1998; 97: 2175-2182.
43. Dichtl W, Nilsson L, Goncalves I, et al: Very low-density lipoprotein activates nuclear factor-κB in endothelial cells. Circ Res 1999; 84: 1085-1094.
44. Sawka AM, Singh RJ, Hiddinga HJ, et al: Remnant lipoproteins induce endothelial plasminogen activator inhibitor-1. Biochem Biophys Res Commun 2001; 285: 15-19.
45. Kifor I, Dzau VJ: Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ Res 1987; 60: 422-428.
46. Kusaka Y, Kelly RA, Williams GH, Kifor I: Coronary microvascular endothelial cells cosecrete angiotensin II and endothelin-1 via a regulated pathway. Am J Physiol 2000; 279: H1087-H1096.
47. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R: Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000; 86: 139-143.
48. Cook JL, Zhang Z, Re RN: In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001; 89: 1138-1146.
49. Halkin A, Keren G: Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 2002; 112: 126-134.